Skip to main content
OpenTrials

Clinical trial condition

Hemorrhagic Disorders

Explore clinical trials studying Hemorrhagic Disorders. Study availability and eligibility vary by location and protocol.

4,580 public trials 828 recruiting studies
Refine in advanced search Browse all conditions

Hemorrhagic Disorders trial results

Recruiting

Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.

NCT07107529

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • IT-Ascoli Piceno-Ospedale Mazzoni [01-016] Ascoli Piceno, Italy
  • IT-Bari-A.O.U. Consorziale Policlinico - Medicina Interna [01-018] Bari, Italy
  • IT-Bergamo-A.O. Papa Giovanni XXIII [01-003] Bergamo, Italy
  • IT-Bologna-A.O.U. di Bologna - Policlinico S. Orsola Malpighi [01-004] Bologna, Italy
View all 29 locations
View Trial Details
Recruiting

SynKIR-310 for Relapsed/Refractory B-NHL

NCT06544265

Conditions
Aggressive B-Cell Non-Hodgkin Lymphoma, B Cell Lymphoma, Blood Protein Disorders, +54 more
Locations
  • Colorado Blood Cancer Institute, part of Sarah Cannon Cancer Institute Denver, Colorado, United States
  • Winship Cancer Institute of Emory University Atlanta, Georgia, United States
  • The University of Kansas Cancer Center Fairway, Kansas, United States
  • Rutgers Cancer Institute New Brunswick, New Jersey, United States
View Trial Details
Recruiting

Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma

NCT07529782

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Beijing Chao-Yang Hospital, Capital Medical University Beijing, Beijing Municipality, China
  • The First Affiliated Hospital of Soochow University Suzhou, Jiangsu, China
  • Qilu Hospital of Shandong University Jinan, Shandong, China
  • Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences Tianjin, Tianjin Municipality, China
View Trial Details

Related conditions